2024
Overall survival in TP53-mutated AML and MDS
Puzo C, Hager K, Rinder H, Weinberg O, Siddon A. Overall survival in TP53-mutated AML and MDS. Annals Of Hematology 2024, 1-11. PMID: 39443370, DOI: 10.1007/s00277-024-06054-7.Peer-Reviewed Original ResearchOverall survivalBlast countTP53 mutationsSignificant predictors of OSP53 mutation typePredictors of OSAggressive disease biologyRetrospective chart reviewKaplan-Meier curvesYale-New Haven HospitalNext generation sequencingCox proportional hazards modelsProportional hazards modelComplex karyotypePoor OSP53 mutationsWHO criteriaChart reviewNew Haven HospitalPoor prognosisCo-mutationsPathogenic mutationsAMLICCS guidelinesMutation type
2019
DUSP22-IRF4 rearrangement in AIDS-associated ALK-negative anaplastic large cell lymphoma
Wang M, Kibbi N, Ring N, Siddon A, Foss F, Totonchy M. DUSP22-IRF4 rearrangement in AIDS-associated ALK-negative anaplastic large cell lymphoma. BMJ Case Reports 2019, 12: e230641. PMID: 31570354, PMCID: PMC6768350, DOI: 10.1136/bcr-2019-230641.Peer-Reviewed Original ResearchConceptsAnaplastic large cell lymphomaPrimary systemic anaplastic large cell lymphomaSystemic anaplastic large cell lymphomaLarge cell lymphomaPoor prognosisSubcutaneous nodulesCell lymphomaGenetic testingALK-negative anaplastic large cell lymphomaBrentuximab vedotin monotherapySetting of HIVHIV-negative patientsCases of AIDSAnaplastic lymphoma kinaseHIV/AIDSComplete remissionDiffuse lymphadenopathyDisease courseFavorable prognosisLymph nodesAggressive lymphomaLymphoproliferative disordersLymphoma kinaseLymphomaAIDS